title: Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers.
abstract: The aim of the current study is an analysis of tumor parameters, clinical and pathological responses, medical management, and survival on 710 operable breast cancer patients who received neoadjuvant chemotherapy from 1982 to 2004 and were grouped into four successive periods according to diagnosis date: (1) 1982-1989; (2) 1990-1994; (3) 1995-1999; and (4) 2000-2004. Patients were treated by different neoadjuvant chemotherapies combinations: AVCF/M, TNCF, NEM, NET, TAXOTERE, FEC 50, 75, 100, FAC 50, and TAXOTERE-TNCF, mainly in successive prospective phase II trials. They received a median number of six cycles (range, 1-9). After primary chemotherapy, patients underwent a surgery and a radiotherapy. In case of significant residual disease, some patients received additional courses of chemotherapy. In addition, menopausal patients with hormonal receptor-positive tumors received tamoxifen for 5 yr. Clinical factors had some remarkable variations with time. The median age of the patients was 49.5 yr (range, 26-81). The size of the tumor was significantly greater from 1995; conversely, clinical lymph-node involvement was lower in period 4 than in the first period. The percentage of invasive ductal carcinoma and of SBR III tumors increased about 20% from 1982-1989 to 2000-2004. The number of positive hormonal receptors increased from 38.3% in period 1 to 74% in period 4. The clinical response rate improved recently from before 1990. The pathological response rate was greater in periods 2 and 3 than in periods 1 and 4. An adjuvant hormonotherapy became progressively more frequently given (44.7 for period 1 and 73.3% for period 4). Finally, no significant difference was found when we compared overall and disease-free survival through the four periods. It appears that the progressive increase of tumor burden was compensated by more effective treatments.
authors.affiliation: Centre Jean Perrin, 58 Rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France. Recherche.clinique@cjp.fr
authors.forename: C
authors.initials: C
authors.lastname: Abrial
authors.forename: M A
authors.initials: MA
authors.lastname: Mouret-Reynier
authors.forename: S
authors.initials: S
authors.lastname: Amat
authors.forename: I
authors.initials: I
authors.lastname: Sillet-Bach
authors.forename: P
authors.initials: P
authors.lastname: Bougnoux
authors.forename: R
authors.initials: R
authors.lastname: Delva
authors.forename: H
authors.initials: H
authors.lastname: Cure
authors.forename: J
authors.initials: J
authors.lastname: Dauplat
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: P
authors.initials: P
authors.lastname: Chollet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D049691:History, Medieval; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D016896:Treatment Outcome